Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norethindrone acetate transdermal delivery system
- Development stage
- Unknown
- Lead developer
- Noven Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
Norethindrone acetate transdermal delivery system (TDS) is an investigational progestin-only contraceptive patch developed by Watson Pharmaceuticals. The active ingredient, norethindrone acetate (NETA), is a synthetic progestin that acts as a potent agonist of the progesterone receptor. By providing a continuous release of the hormone through the skin, the system aims to prevent pregnancy primarily by suppressing ovulation, increasing the viscosity of cervical mucus to impede sperm penetration, and altering the endometrial lining to discourage implantation. This formulation was evaluated in Phase 3 clinical trials, such as the 'Simplify' study, as a convenient alternative to daily oral contraceptive pills. While Watson Pharmaceuticals marketed oral progestin-only contraceptives like NOR-QD, this specific transdermal system was designed to offer the benefits of a patch-based delivery for contraception.
- Other names
- norethindrone acetate patchnorethindrone acetate transdermal system
02
Targets
PR (Progesterone receptor)AR (Adrenergic receptors)ER (Estrogen receptor)
Beyond the preview
Go deeper on norethindrone acetate transdermal delivery system.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norethindrone acetate transdermal delivery system.